Johnson & Johnson (JNJ)vsProthena Corporation plc (PRTA)
JNJ
Johnson & Johnson
$255.88
-3.66%
HEALTHCARE · Cap: $615.36B
PRTA
Prothena Corporation plc
$8.41
-1.75%
HEALTHCARE · Cap: $448.14M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 168918% more annual revenue ($97.93B vs $57.94M). JNJ leads profitability with a 21.5% profit margin vs -260.9%. PRTA appears more attractively valued with a PEG of 0.80. PRTA earns a higher WallStSmart Score of 58/100 (C).
JNJ
Buy57
out of 100
Grade: C
PRTA
Buy58
out of 100
Grade: C
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 28.6%
Generating 3.4B in free cash flow
Reasonable price relative to book value
Strong operational efficiency at 50.5%
Revenue surging 1706.0% year-over-year
Conservative balance sheet, low leverage
Growing faster than its price suggests
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 1.0%
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -48.4% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 28.6%.
Bull Case : PRTA
The strongest argument for PRTA centers on Price/Book, Operating Margin, Revenue Growth. Revenue growth of 1706.0% demonstrates continued momentum. PEG of 0.80 suggests the stock is reasonably priced for its growth.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : PRTA
The primary concerns for PRTA are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
JNJ profiles as a mature stock while PRTA is a hypergrowth play — different risk/reward profiles.
JNJ carries more volatility with a beta of 0.23 — expect wider price swings.
PRTA is growing revenue faster at 1706.0% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
PRTA scores higher overall (58/100 vs 57/100) and 1706.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Prothena Corporation plc
HEALTHCARE · BIOTECHNOLOGY · USA
Prothena Corporation plc, an advanced stage clinical company, is focused on the discovery and development of new therapies for life-threatening diseases in the United States. The company is headquartered in Dublin, Ireland.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?